135 related articles for article (PubMed ID: 32389233)
1. Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials.
Giesinger JM; Blazeby J; Aaronson NK; Sprangers M; Fayers P; Sparano F; Rees J; Anota A; Wan C; Pezold M; Isharwal S; Cottone F; Efficace F;
Value Health; 2020 May; 23(5):666-673. PubMed ID: 32389233
[TBL] [Abstract][Full Text] [Related]
2. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making.
Van Hemelrijck M; Sparano F; Moris L; Beyer K; Cottone F; Sprangers M; Efficace F
Cancer Med; 2020 Jun; 9(12):4039-4058. PubMed ID: 32333639
[TBL] [Abstract][Full Text] [Related]
4. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G).
Smith AB; Cocks K; Parry D; Taylor M
Qual Life Res; 2014 Apr; 23(3):971-6. PubMed ID: 24097080
[TBL] [Abstract][Full Text] [Related]
5. Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.
Mouillet G; Efficace F; Thiery-Vuillemin A; Charton E; Van Hemelrijck M; Sparano F; Anota A
Cancer Med; 2020 Oct; 9(20):7363-7374. PubMed ID: 32846465
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcome Measures in Liver and Gastrointestinal Cancer Randomized Controlled Trials.
Winkelmann C; Mezentseva A; Vogt B; Neumann T
Int J Environ Res Public Health; 2023 Jul; 20(13):. PubMed ID: 37444140
[TBL] [Abstract][Full Text] [Related]
8. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
[TBL] [Abstract][Full Text] [Related]
9. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
[TBL] [Abstract][Full Text] [Related]
10. Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review.
Giesinger JM; Efficace F; Aaronson N; Calvert M; Kyte D; Cottone F; Cella D; Gamper EM
Value Health; 2021 Apr; 24(4):585-591. PubMed ID: 33840437
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
12. Updated EORTC QLQ-C30 general population norm data for Germany.
Nolte S; Waldmann A; Liegl G; Petersen MA; Groenvold M; Rose M;
Eur J Cancer; 2020 Sep; 137():161-170. PubMed ID: 32777715
[TBL] [Abstract][Full Text] [Related]
13. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
14. Cancer patients' understanding of longitudinal EORTC QLQ-C30 scores presented as bar charts.
Loth FL; Holzner B; Sztankay M; Bliem HR; Raoufi S; Rumpold G; Giesinger JM
Patient Educ Couns; 2016 Dec; 99(12):2012-2017. PubMed ID: 27506581
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
16. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
19. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
Ediebah DE; Quinten C; Coens C; Ringash J; Dancey J; Zikos E; Gotay C; Brundage M; Tu D; Flechtner HH; Greimel E; Reeve BB; Taphoorn M; Reijneveld J; Dirven L; Bottomley A;
Cancer; 2018 Aug; 124(16):3409-3416. PubMed ID: 29905936
[TBL] [Abstract][Full Text] [Related]
20. Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment.
Herman JM; Kitchen H; Degboe A; Aldhouse NVJ; Trigg A; Hodgin M; Narang A; Johnson CD
Qual Life Res; 2019 Nov; 28(11):2929-2939. PubMed ID: 31273624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
